Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

12 Issues per year


IMPACT FACTOR 2014: 2.707
Rank 6 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR): 0.860
Source Normalized Impact per Paper (SNIP): 1.046

VolumeIssuePage

Issues

Comparison of Different CD71 Monoclonal Antibodies for Enrichment of Fetal Cells from Maternal Blood

Belén Prieto / Mercedes Cándenas / Jack H. Ladenson / Francisco V. Álvarez

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 40, Issue 2, Pages 126–131, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2002.022, June 2005

Publication History

Published Online:
2005-06-01

Abstract

Different approaches have been proposed for the enrichment of fetal nucleated red blood cells (NRBC) from maternal blood as an alternative way to obtain fetal tissue for non-invasive prenatal diagnosis. The main purpose of this study was to compare two of our monoclonal antibodies (2E11.3 and 2B7.4 mAbs) with the most widely used commercial anti-CD71 mAb, in terms of their ability to isolate NRBC from maternal blood by magnetic activated cell sorting (MACS). Peripheral blood samples were obtained from 60 pregnant women at a mean gestational age of 16 weeks (range: 10–19 weeks). The number of NRBC isolated by our antibodies (median: 68, range: 0–2102) was significantly higher than that obtained by the commercial antibody (median: 38, range: 0–2165) in the same samples. However, in the final preparations, contamination by maternal nucleated blood cells was lower when the commercial antibody was used. Since fetal NRBC are rare in maternal blood, the improved NRBC recovery achieved by our non-commercial antibodies should facilitate the non-invasive detection of fetal aneuploidies in maternal blood.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Marie Brinch, Lotte Hatt, Ripudaman Singh, Kristine Møller, Steffen Sommer, Niels Uldbjerg, Britta Christensen, and Steen Kølvraa
Prenatal Diagnosis, 2012, Volume 32, Number 8, Page 742
[2]
Alejandra Fernández Fernández, Belén Prieto García, and Francisco V. Álvarez Menéndez
Revista del Laboratorio Clínico, 2009, Volume 2, Number 1, Page 47
[3]
Sinuhe Hahn, Xiao Yan Zhong, and Wolfgang Holzgreve
Seminars in Fetal and Neonatal Medicine, 2008, Volume 13, Number 2, Page 57
[4]
Belén Prieto, Mercedes Cándenas, Rafael Venta, Jack H. Ladenson, and Francisco V. Álvarez
Clinical Chemistry and Laboratory Medicine, 2002, Volume 40, Number 7
[5]
Bibi Shahnaz Aali, Reza Malekpour, Fatemeh Sedig, and Abbas Safa
Journal of Obstetrics and Gynaecology Research, 2007, Volume 33, Number 3, Page 274
[6]
Nicoletta Di Simone, Marco Lai, Carlo Rumi, Patrizia Riccardi, Marco D’Asta, Giuseppe Leone, Salvatore Mancuso, and Alessandro Caruso
Fetal Diagnosis and Therapy, 2006, Volume 21, Number 5, Page 404
[8]
Prenatal Diagnosis, 2002, Volume 22, Number 8, Page 740

Comments (0)

Please log in or register to comment.